Comparative Pharmacology
Head-to-head clinical analysis: NYDRAZID versus PASER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NYDRAZID versus PASER.
NYDRAZID vs PASER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by blocking the incorporation of mycolic acid into the arabinogalactan layer, specific to mycobacteria.
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
300 mg orally once daily; alternatively, 5 mg/kg (max 300 mg) orally once daily for 6-9 months for latent tuberculosis; for active tuberculosis, 5 mg/kg (max 300 mg) orally once daily for 2 months followed by 3 times weekly dosing (15 mg/kg, max 900 mg) for 4-7 months.
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
None Documented
None Documented
Terminal elimination half-life: 1-4 hours (fast acetylators), 2-8 hours (slow acetylators). Half-life prolonged in hepatic impairment; adjust dose.
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (CrCl <10 mL/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Renal excretion of unchanged drug and metabolites; 50-70% excreted in urine within 24 hours, mainly as acetylisoniazid and isonicotinic acid. Biliary/fecal: <10%.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
Category C
Category C
Antitubercular Agent
Antitubercular Agent